PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 158 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2018. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $114,000 | -29.6% | 30,034 | -6.4% | 0.00% | – |
Q4 2019 | $162,000 | -41.1% | 32,079 | -41.3% | 0.00% | – |
Q3 2019 | $275,000 | -92.2% | 54,616 | -90.4% | 0.00% | -100.0% |
Q2 2019 | $3,521,000 | -43.3% | 571,151 | -57.3% | 0.00% | -50.0% |
Q1 2019 | $6,207,000 | +686.7% | 1,337,894 | +611.2% | 0.00% | +300.0% |
Q4 2018 | $789,000 | -81.3% | 188,129 | -72.0% | 0.00% | 0.0% |
Q3 2018 | $4,212,000 | +25.2% | 671,812 | +60.5% | 0.00% | 0.0% |
Q2 2018 | $3,365,000 | +23.8% | 418,631 | +14.8% | 0.00% | 0.0% |
Q1 2018 | $2,718,000 | +143.3% | 364,525 | +93.9% | 0.00% | 0.0% |
Q4 2017 | $1,117,000 | -60.4% | 187,998 | -51.0% | 0.00% | -50.0% |
Q3 2017 | $2,819,000 | -40.5% | 383,360 | -45.1% | 0.00% | -33.3% |
Q2 2017 | $4,737,000 | +7.3% | 697,834 | +49.2% | 0.00% | 0.0% |
Q1 2017 | $4,414,000 | +25.6% | 467,724 | +14.9% | 0.00% | 0.0% |
Q4 2016 | $3,515,000 | +34.7% | 407,072 | -1.3% | 0.00% | +50.0% |
Q3 2016 | $2,609,000 | +119.6% | 412,400 | +46.3% | 0.00% | +100.0% |
Q2 2016 | $1,188,000 | +77.0% | 281,946 | +83.0% | 0.00% | 0.0% |
Q1 2016 | $671,000 | -31.9% | 154,082 | -4.2% | 0.00% | 0.0% |
Q4 2015 | $985,000 | -64.2% | 160,838 | -66.6% | 0.00% | -50.0% |
Q3 2015 | $2,752,000 | +43.6% | 481,488 | +87.2% | 0.00% | +100.0% |
Q2 2015 | $1,916,000 | +44.3% | 257,168 | +15.7% | 0.00% | 0.0% |
Q1 2015 | $1,328,000 | -52.3% | 222,366 | -39.7% | 0.00% | -50.0% |
Q4 2014 | $2,786,000 | +87.6% | 368,976 | +28.8% | 0.00% | +100.0% |
Q3 2014 | $1,485,000 | +47.3% | 286,450 | +22.4% | 0.00% | 0.0% |
Q2 2014 | $1,008,000 | -5.1% | 234,011 | -10.0% | 0.00% | 0.0% |
Q1 2014 | $1,062,000 | -39.8% | 260,124 | -21.5% | 0.00% | 0.0% |
Q4 2013 | $1,764,000 | -29.7% | 331,382 | -33.8% | 0.00% | -50.0% |
Q3 2013 | $2,511,000 | – | 500,620 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |